Summary Uncertainty remains over whether or not high intakes of retinol or vitamin A consumed through food or supplements may increase fracture risk. This intervention study found no increase in fracture risk among 2,322 adults who took a controlled, high-dose retinol supplement (25,000 IU retinyl palmitate/day) for as long as 16 years. There was some evidence that beta-carotene supplementation decreased fracture risk in men. Introduction There is conflicting epidemiological evidence regarding high intakes of dietary or supplemental retinol and an increased risk for bone fracture. We examined fracture risk in a study administering high doses of retinol and betacarotene (BC) between 1990 and 2007. Methods The Vitamin A Program was designed to test the efficacy of retinol and BC supplements in preventing malignancies in persons previously exposed to blue asbestos. Participants were initially randomised to 7.5 mg retinol equivalents (RE)/day as retinyl palmitate, 30 mg/day BC or 0.75 mg/day BC from 1990 to 1996; after which, all participants received 7.5 mg RE/day. Fractures were identified by questionnaire and hospital admission data up until 2006. Risk of any fracture or osteoporotic fracture according to cumulative dose of retinol and BC supplementation was examined using conditional logistic regression models adjusting for age, sex, smoking, body mass index, medication use and previous fracture. Results Supplementation periods ranged from 1 to 16 years. Of the 2,322 (664 females and 1,658 males) participants, 187 experienced 237 fractures. No associations were observed between cumulative dose of retinol and risk for any fracture (OR per 10 g RE00.83; 95 % CI, 0.63-1.08) or osteoporotic fracture (OR per 10 g RE00.95; 95 % CI 0.64-1.40). Among men, cumulative dose of BC was associated with a slightly reduced risk of any fracture (OR per 10 g0 0.89; 95 % CI 0.81-0.98) and osteoporotic fracture (OR per 10 g00.84; 95 % CI 0.72-0.97). Conclusions This study observed no increases in fracture risk after long-term supplementation with high doses of retinol and/or beta-carotene.
Introduction
Dietary retinol is essential for growth, night vision and normal cell differentiation [1] . However, it is well documented that chronic high doses of retinol induce osteopenia and fractures in laboratory animals [1, 2] . Excess retinol is thought to increase bone turnover and bone fragility via retinoic acid, the active metabolite that influences the genetic expression of osteoblasts and osteoclasts [3] . Excess retinoic acid is also thought to interact negatively with 1,25-dihydroxyvitamin D (vitamin D) and serum calcium levels [2, 4] . While most animal studies have administered very high chronic doses to young growing animals, 'subchronic' doses of retinol have also been shown to cause bone thinning and a tendency to fracture in mature animals [5] .
In humans, impaired bone remodelling and bone abnormalities have mainly been associated with cases of accidental overdosing or chronic retinol toxicity [6, 7] . However, the potential for subclinical retinol toxicity to increase fracture risk in humans has been recognised [8] . This is particularly relevant in developed countries with ageing populations, where osteoporosis is a public health problem, and where it is not difficult to achieve high retinol intakes owing to the common consumption of supplements that contain retinol.
A number of observational studies have examined dietary and supplementary intakes of retinol and fracture risk. In the Swedish Mammography Cohort, dietary retinol intakes greater than 1.5 mg/day were associated with a doubling in hip fracture risk (RR02.05, 95 % CI 1.05-3.98) [3] . In the US Nurses Health Study, dietary retinol intakes >1 mg/day were also associated with an increased hip fracture risk (RR01.69; 95 % CI, 1.05-2.74) [9] . Similarly, two cohort studies have reported an increased fracture risk among men [10] and women [11] with high concentrations of serum retinol. Whereas other cohort studies, including the Women's Health Initiative Observational Study [12] , the Danish Osteoporosis Prevention Study [13] , the Iowa Women's Health Study [14] and a UK prospective study of hip fracture in elderly women [15] found no relationship between dietary retinol and fracture risk. The Iowa Women's Health Study reported an increased hip fracture risk among vitamin A supplement users only (RR01.18, 95 % CI, 0.99-1.41) [14] . The only published human experimental study (to date) reported no difference in biomarkers of bone turnover between healthy men, aged 18 to 58 years, who were randomised to a placebo or 7.5 mg/day of retinol (as retinyl palmitate) for 6 weeks [16] . Although retinol and betacarotene both contribute to vitamin A intake, not all betacarotene is converted to retinol, and so they do not necessarily have the same effect on bone. A protective relationship has been suggested between beta-carotene (a precursor of vitamin A) and fracture risk in two observational studies [17, 18] , possibly through its antioxidant capability [17] .
Given the lack of large, extended experimental studies examining retinol and bone health, we conducted an exploratory analysis of fracture risk as a secondary endpoint, using data from a cancer prevention study that administered high doses of retinol and/or beta-carotene supplements to asbestos-exposed members of the general population between 1990 and 2007. We hypothesised that (1) longer supplementation with a high dose of retinol would be associated with an increased fracture risk and (2) longer supplementation with a high dose of beta-carotene (BC) would be associated with a decreased fracture risk.
Methods
The Vitamin A Program was an intervention study designed to test the efficacy of high-dose retinol and beta-carotene supplements for reducing the risk of mesothelioma and lung cancer (primary outcomes) in persons previously exposed to crocidolite (blue asbestos). The study was conducted in Perth, Western Australia (WA) between 1990 and 2007 [19, 20] . Participants were eligible for the study if they had experienced occupational and/or environmental crocidolite exposure as former workers or residents of the remote town of Wittenoom (WA), where crocidolite was mined and milled by the Australian Blue Asbestos Company from 1943 until 1966 [21] . Since 1979, former Wittenoom worker and resident cohorts have been followed up for incidence of asbestos-related diseases: asbestosis, malignant mesothelioma and lung cancer [22, 23] . In July 1990, all surviving cohort members were invited to take part in the Vitamin A Program [20] .
Consenting former Wittenoom workers were randomly assigned to take either 30 mg/day of synthetic all-trans BC or 7.5 mg retinol equivalents (RE)/day as retinyl palmitate (25,000 IU). Many members of the former resident cohort were women of reproductive age for whom a high-dose retinol supplement was considered contraindicated. For this reason, all former residents were initially randomised to either 30 or 0.75 mg/day synthetic all-trans BC. These two parallel regimens, conducted between 1990 and 1996, represent phase 1 of the Program (Fig. 1) . All supplements were provided by Roche Pharmaceuticals and the study was single-blinded (participants).
At the end of 1995, preliminary analyses showed a reduced risk of mesothelioma among participants in the study who were randomised to 7.5 mg RE/day retinol (RR00.24, 95 % CI 0.07-0.86) [20] . At around the same time, adverse effects were being reported from similar doses of BC in trials examining lung cancer risk [24, 25] . Therefore, in September 1996, administration of BC supplements ceased and all study participants were requested to stop taking their BC supplements. The Vitamin A Program ceased briefly but recommenced in July 1997, from which point all study participants were administered with 7.5 mg RE/day of retinol as retinyl palmitate (phase 2, Fig. 1 ). Women of childbearing age who had not undergone surgical sterilisation and participants with abnormal liver function were supplemented with 1.5 mg RE/day of retinol as retinyl palmitate (5,000 IU). A very small number of participants had to change dose after commencing the Vitamin A Program due to changes in individual circumstances and participants were continually recruited into the study (not shown in Figure 1 ).
Annual follow-ups
At entry to the Vitamin A Program, the participants were interviewed and provided occupational, smoking and medical histories. Height and weight were measured and a chest X-ray was taken. Thereafter, all participants were invited to attend an annual clinic visit to collect information on compliance with the administered supplement (self-report and capsule count), consumption of other vitamin supplements, prescribed medications, physical activity, serious illnesses and smoking habits. Possible side effects were monitored annually using a symptom questionnaire and blood tests for liver function. Participants unable to attend their annual interview returned questionnaires by mail.
Fractures
Fracture risk was not a primary outcome in the Vitamin A Program. An interest in fracture risk was brought about by earlier reports of high vitamin A intake and increased fracture risk in observational studies [3, 9] . Fracture incidence was estimated using hospital admissions for fracture by linking the resident and worker cohorts with the Western Australian hospital morbidity database (Data Linkage Western Australia [26] ), which at that time was current up until 31 December 2005. Admissions for fracture were identified using International Classification of Diseases (ICD) codes: ICD 10M80.0-M81.9 (osteoporosis with and without pathological fracture), M84.3, M84.4, S02-S02.9, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T08, T10, T12, T14.2 (from July 1999) and ICD 9 733.0 733.1 800-829 (from 1990 to July 1999). Hospital admissions ascertain the most serious fractures. Because not all fractures require hospitalisation, a self-administered questionnaire on fracture history (modelled on one used in a previous Australian study of fractures [27] ) was posted to all surviving Program participants for completion in June 2007 (n 01,791). Respondents were asked to record details of all fractures during their lifetime, how the fracture occurred, if they sought medical treatment and if they were hospitalised. This questionnaire also collected information on serious illnesses, smoking history, lifetime vitamin supplement use and prescribed medication use, specifically, thyroid drugs, diuretics, corticosteroids (inhaled and oral), anabolic steroids, hormone replacement therapy, sedatives, tranquilisers, anti-coagulants, chemotherapy and medications for bone health (i.e. those used for calcium deficiency, osteoporosis or renal dialysis), epilepsy, depression and anxiety. Selfreported fractures occurring at the spine, hip, femur, arm, ribs or wrist were classified as osteoporotic fractures [28] . Where self-reported fracture dates differed from hospital admission records, the latter was used.
All participants gave their informed consent to participate in the Vitamin A Program. The study, including record linkage and study questionnaires, was approved by The University of Western Australia's Human Research Ethics Committee and the Clinical Drug Trials Committee of the Sir Charles Gairdner Hospital, Nedlands, Western Australia.
Statistical analyses
Participants were followed up from the date they commenced until withdrawal from the study, date of death, or 31 December 2005, whichever occurred first. Only incident fractures were included as outcomes, i.e. those that occurred after commencement of the study and before 31 December 2005, corresponding to the date that record linkage followup ended. Fractures occurring before commencing the study were treated as 'previous' fractures.
Two primary outcomes were analysed: the risk of fracture occurring at an osteoporotic site and the risk of any fracture. Study participant characteristics were compared by fracture outcome using chi-squared tests and t tests in PASW Statistics (v18.0.0). Conditional logistic regression models with matching for calendar year were used to examine the risk of any fracture and osteoporotic fracture according to cumulative doses of administered retinol and BC supplements (Stata, v10.1). It is computationally quicker and easier to fit models with time-varying covariates using conditional logistic regression than Cox regression, and the partial likelihood in the Cox's method and the conditional likelihood from the conditional method are algebraically equivalent [29] . Repeated measurements of the following were treated as time-varying covariates: annual cumulative dose of retinol and BC supplements, age, body mass index (BMI), smoking pack-years and previous fracture (which increased in the case of having more than one fracture during followup). Cumulative doses of retinol and BC supplements were estimated by summing the number of days the allocated supplement was taken between each annual follow-up (taking account compliance and any changes in supplement or dose), multiplying by the dose administered and adding to the previous year's total. Cumulative doses of retinol were analysed in units of 10 g RE (retinol was converted from International Units assuming 10,000 IU retinyl palmitate is equivalent to 3 mg RE [30] ). Cumulative doses of BC were analysed in units of 10 g. Gender, ever smoked and the use of medications for bone health were examined as fixed variables. Other medication types were not considered owing to their being very few users. Age, gender, BMI and smoking were included in all models as these are known risk factors for osteoporosis [31] . All tests for statistical significance used an alpha level of 0.05.
Results
Of the 2,346 former workers and residents of Wittenoom who participated in the Program, 2,322 (99 %) had a known fracture outcome for one or more years of follow-up (664 females and 1,658 males). The study population was predominantly male (71 %) and the mean age when joining the study was 55 years (Table 1) . Follow-up times ranged from 1 to 16 years (median, 7 years). The maximum cumulative dose of retinol was 42 g RE, equivalent to taking 7.5 mg RE/ day for 15.3 years. For BC, the maximum cumulative dose was 80.6 g, equivalent to taking 30 mg BC/day for 7.3 years. The mean cumulative dose of retinol and the mean number of annual follow-ups were higher among those who experienced a fracture during follow-up, compared with those without fracture. Those who had fractures were also more likely to have had a fracture before commencing the Program (overall 22.6 % reported at least one prior fracture) and to have taken medication for bone health (indicated for calcium deficiency, osteoporosis or renal dialysis).
Side effects related to skin dryness, nausea or headache were reported by 12 % of the participants, and of these, 1.2 % withdrew from the study. Increased liver function (raised gamma glutamyl transferase or aspartate aminotransferase concentration) was observed in 12 % of the participants after commencing the study, and of these, 1.3 % withdrew from the study as a result.
Of the 2,322 participants with known fracture status, 187 experienced at least one fracture during follow-up, 30 participants had two fractures and 1 had six (Table 2) . Most fractures (63 %) occurred in men. Forty percent of fractures (n 095) were at osteoporotic sites. Thirty-nine percent (39.3 %) of participants (of which, 90 % were male) were administered with a retinol and a BC supplement at some stages during follow-up, 33.4 % (of which, 76 % were male) were administered retinol only and 27.3 % (of which, 67 % were male) were administered BC only; the fracture rates within these groups were 13.6, 6.6 and 1.9 %, respectively.
Univariate conditional logistic regression analyses (n0 2,322 subjects) showed no significant relationships between supplementation with retinol or BC and fracture risk (any or osteoporotic fracture) ( The multivariate conditional logistic regression model (n0 1,743 subjects) included age, sex, smoking pack-years, BMI, medications for bone health, previous fractures and cumulative dose of retinol and BC supplement at each follow-up. Functional forms of these covariates and interactions were investigated and only an interaction between sex and BC was statistically significant (p00. (Table 3 ). However, the interaction revealed a reduction in fracture risk with increasing cumulative dose of BC in males (per 10 g BC: any fracture OR00.89, 95 % CI 0.81-0.98, p00.014; osteoporotic fracture OR00.84, 95 % CI 0.72-0.97, p00.022) ( Table 3) . Each previous fracture (any fracture OR01.27, 95 % CI 1.14-1.42, p<0.001; osteoporotic fracture OR01.31, 95 % CI 1.12-1.55) and the use of medications for bone health (any fracture OR01.81, 95 % CI 1.16-2.82, p00.009; osteoporotic fracture OR02.03, 95 % CI1.06-3.90 ) were associated with greater fracture risk, but age (p00.48; p00.61 for any and osteoporotic fracture, respectively), sex (p00.39; p00.57), smoking pack-years (p00.35; p00.51) and BMI (p00.69; p00.92) were not associated with fracture risk in the multivariate models.
Discussion
In this intervention study, we did not observe positive associations between fracture risk and duration of supplementation with high doses of retinyl palmitate, for up to 16 years. However, a decreased risk of fracture (any and osteoporotic site) was associated with a greater duration of beta-carotene supplementation in men.
There have been very few experimental studies of supplemental retinol and bone health in humans. Kawahara et al. randomised 80 screened, healthy men aged 18 to 58 years of age to a placebo or 25,000 IU (7.5 mg RE) of retinol palmitate per day, the same daily dose of retinol administered in the present study, for 6 weeks [16] . There were no differences in bone turnover (serum osteocalcin, bonespecific alkaline phosphatase and N-telopeptide of type-1 collagen) between the supplemented and placebo groups at weeks 2, 4 and 6. However, this study was short in relation to the 4-to 6-month turnover of the bone remodelling unit [32] , and the young, healthy male subjects were at a low risk for osteoporosis. A case-control study examined the use of prescription vitamin A analogues (isotretinoin and acitretin as well as topical vitamin A analogues) using a population-based registry of drugs sold at pharmacies and hospitalisation for fractures for the whole of Denmark in 2005 [33] . They found no increase in fracture risk with dose of retinoid drug prescribed, duration of therapy or cumulative dose. However, unlike the retinol supplement administered in the present study, synthetic analogues of retinol are used as therapeutic agents and do not occur naturally in foods nor are they added to foods or vitamin supplements.
Observational studies examining vitamin A supplement use in relation to fracture risk have been mixed. A slightly increased risk for self-reported hip fracture, but not all fractures, was suggested among vitamin A supplement users (RR01.18, 95 %CI, 0.99-1.41) in the Iowa Women's Health Study, which followed up over 34,000 post-menopausal women for an average of 9.5 years [14] . However, no dose-response relationship was demonstrated, and hip fracture was not associated with dietary or total retinol intake [14] . In the placebo arm of a UK trial of bisphosphonate clodronate to prevent hip fracture in elderly women, 312 fractures were identified (of which 92 were hip fractures) during an average of 3.7 years of follow-up. Vitamin A supplement users were reported to have a decreased risk for any fracture (HR00.76, 95 % CI, 0.60-0.96) but not hip fracture (HR00.85, 95 % CI 0.56-1.33) [15] . In a small case-control study of 229 post-menopausal women living in a geographically defined area of Iowa (n098 cases), vitamin A supplement users (n089) did not have an increased risk for self-reported fracture [34] .
Two large cohort studies have reported positive associations between dietary retinol intake and fracture risk. The Swedish Mammography Cohort Study included 60,651 women aged 40 to 76 years and residents in two Swedish counties [3] . Retinol intakes were estimated using an evaluated food frequency questionnaire (FFQ) that collected information on the consumption of 60 foods over the previous 6 months and assumed standard portion sizes. A nested case-control analysis included 247 women hospitalised for a hip fracture within 64 months of study enrolment and 873 age-matched controls. Dietary retinol intake above 1.5 mg/ day was associated with an increased risk for hip fracture (RR02.05, 95 % CI 1.05-3.98), after adjustments for BMI, leisure time physical activity, smoking, HRT use, cortisone use, other supplement use, diabetes, menopause factors, previous fractures and total energy intake. This study also reported an inverse cross-sectional association between retinol intake and bone mineral density. The US Nurses Health Study examined self-reported hip fracture (n0603) during 18 years of follow-up (860,355 person-years) [9] . Estimates of dietary retinol were made on five occasions between 1980 and 1994 using a validated semi-quantitative FFQ. Vitamin supplement use was common, and the mean retinol intake from food and supplements was 1.2 mg RE/day, ranging from 0.09 to 8.8 mg RE/day. After adjustment for BMI, smoking, leisure time activity, HRT and diuretics use, those in the highest quintile of dietary retinol intake (>1.0 mg RE/day) had a RR of 1.69 (95 % CI, 1.05-2.74, p for trend00.05) for incident hip fracture. Being in the highest quintile of retinol intake including food and supplements (>2 mg RE/day) was associated with a RR of 1.89 (95 % CI, 1.33-2.68, p for trend<0.001). More recent cohort studies have not observed associations between dietary or supplementary retinol intake and fracture risk. The Women's Health Initiative Observational Study included over 75,000 post-menopausal women, in which 10,400 self-reported fractures were identified during an average of 6.6 years of follow-up [12] . Total retinol intake (food and supplements) was measured on two occasions with a semi-quantitative FFQ, and was not associated with risk for any fracture or hip fracture, although medication use was not considered in the analysis. There was however, a slightly elevated total fracture risk (RR01.15, 95 % CI, 1.03-1.29) among women in the highest quintile of estimated total retinol intake (≥1.43 mg/day) who had a low vitamin D intake (≤11 μg/day). The Danish Osteoporosis Prevention Study examined self-reported fractures and dietary retinol intake measured using a food record [13] . Their nested case-control analysis included 163 cases with six controls matched to each case according to HRT use. Fracture risk was not associated with dietary retinol intake or total retinol intake before or after adjustment for lifestyle factors and medication use; however, retinol intakes in this study were lower than those reported in other studies.
It has been hypothesised that carotenoids may reduce fracture risk by counteracting oxidative stress, which can adversely affect bone mineral density [17] . Our finding of a decreased fracture risk with longer duration of BC supplementation, albeit in men only (possibly because of the small number of women in our study), is in line with these observational studies. Based on 100 hip fractures occurring during 17 years of follow-up, the Framingham Osteoporosis Study reported a lower fracture risk (HR00.54, 95 % CI 0.32-0.90) among subjects having the highest total dietary carotenoid intakes [17] . The Utah Study of Nutrition and Bone Health, a case-control study of 1,215 fractures, reported a significantly lower risk for osteoporotic fracture among smokers in the highest quintile of beta-carotene intake (OR00.39, 95 % CI 0.23-0.68) [18] .
To our knowledge, no other intervention studies have been published to date where controlled, high doses of retinol have been administered over many years. The doses administered in this study are well above typical population level dietary intakes and recommended intakes. In Australia, the recommended dietary intake for vitamin A is 700 μg RE/day for non-pregnant females and 900 μg RE/day for males [35] . The daily dose of 7.5 mg RE administered in this study is equivalent to eight to ten times higher than these recommended amounts and almost four times higher than the highest level of total retinol intake associated with an increased fracture risk in observational studies (2 mg RE/ day [9] ). Thus, the magnitude of retinol administered in the present study increased the likelihood of detecting an increased risk of fracture and avoided the measurement error associated with estimated dietary intakes.
To date, all of the observational studies that have investigated dietary or supplementary retinol and fracture risk have included women only, with the majority focussing on post-menopausal women. The present study includes both men and women of a wide range of ages. Whereas the majority of studies have relied on self-report, the present analysis used both self-report and hospital admission data to ascertain fracture incidence. In addition, the long follow-up in this study increased the likelihood of detecting incident fractures.
Although this study benefits from an experimental design, it was not possible to utilise a randomised controlled trial design in this analysis. The primary purpose of the original study (cancer prevention in a very high-risk population) and nature of the exposure (beta-carotene and retinol are nutrients found widely in food) did not support the use of a placebo. Randomisation was not possible beyond phase 1, and therefore, confounding of the relationships between retinol and beta-carotene and fracture risk cannot be ruled out. Our estimates of compliance with the administered supplement, and hence, estimated cumulative doses, depended on self-report, may have been subject to error or reporter bias. The circumstances (traumatic or nontraumatic) of all fractures were not determined; however, we conducted separate analyses of fractures typically classified as osteoporotic. We were unable to collect information on self-reported fractures from those study participants who withdrew or died before the fracture questionnaire was administered in 2007. This may have resulted in some survivor bias among those who were surveyed and led to the underestimation of self-reported fracture rates in the study population. However, we were able to objectively ascertain hospitalised fractures, i.e. the most serious fractures, such as hip fracture, for all study participants up until the end of 2005. The relatively low number of fractures in this study may be due to the slightly younger age of participants and the high proportion of men (71 %). However, the doses of retinol administered were well above intakes reported in observational studies and the long follow-up allowed for fractures to be detected, yet there was no suggestion of a positive relationship between retinol or BC supplementation and fracture risk.
In conclusion, this intervention study observed no increases in fracture risk after supplementation with betacarotene or retinol for as long as 16 years. As such, this study does not support previous reports of an increased fracture risk with higher intakes of dietary retinol. Conflicts of interest None.
